By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biodesix, Inc. 

2970 Wilderness Place
Suite 100
Boulder  Colorado  80301  U.S.A.
Phone: 303-417-0500 Fax: n/a



Company News
Biodesix, Inc. Release: Lung Cancer Journal: VeristratProteomic Test Improves Overall Survival And Decreases Medical Costs For Patients With Advanced NSCLC 3/24/2015 11:07:23 AM
Biodesix, Inc. And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer 3/11/2015 8:59:51 AM
Biodesix, Inc. Builds On Investments In Sales, Reimbursement And Government Affairs Growth Strategy 2/18/2015 10:52:18 AM
Biodesix, Inc. Nabs $12 Million Series E Financing 1/12/2015 6:10:01 AM
Biodesix, Inc. Announces Inclusion Of Veristrat In Updated NCCN Guidelines 10/24/2014 10:45:50 AM
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Exploratory Analysis Of Veristrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress 9/29/2014 12:17:49 PM
Biodesix, Inc. Receives Highmark Blue Cross Blue Shield Coverage For VeriStrat Test 9/9/2014 10:48:11 AM
Biodesix, Inc. Announces Publication Of Seminal PROSE Study In The Lancet Oncology 5/13/2014 8:38:16 AM
AVEO Oncology (AVEO), Biodesix, Inc. Strike Ficlatuzumab-Companion Diagnostic Pact, Bioesix To Put Up An Initial $15 Million To Fund Study 4/10/2014 6:57:50 AM
Biodesix, Inc. Receives CE Mark For Veristrat Specimen Collection And Shipping Kit 3/3/2014 7:04:37 AM